Skip to main content
. Author manuscript; available in PMC: 2022 May 15.
Published in final edited form as: Clin Cancer Res. 2021 Sep 13;27(22):6235–6249. doi: 10.1158/1078-0432.CCR-21-0971

Figure 5.

Figure 5

(A) Percent killing of MOC2 tumor cells in vitro by NK cells harvested from the spleens of C57BL/6 mice by negative selection; n=5. (B) Flow cytometric analysis of in vitro NK cell populations; *p≤0.05, **p≤0.01; n=5. (C) Expression of CD122 and IL-2RB on NK cells treated in vitro; n=5. (D) Quantitation of IL-2 in the supernatant of isolated NK cells stimulated with or without anti-CD25; n=6. (E) Western blot of immunoprecipitated CD122 probed with anti-phosphotyrosine. CD122 was immunoprecipitated from NK cells isolated from C57BL/6 mice and stimulated with anti-CD25 and IL-2 as indicated. (F) Concentrations of IL-2 in serum of C57BL/6 mice; *p≤0.05; n=6. (G) Concentration of FLT3L in the supernatant of NK cells stimulated with exogenous IL-2 (ELISA) as indicated; *p≤0.05, ***p≤0.001; n=6. (H) Volumes of MOC2 tumors in mice treated with RT, anti-CD25, anti-CD137, and FLT3L hydrodynamic delivery; n=7.